mild side effects of Humira may include injection site reactions, such as: Studies show the most common long-term risks include serious infections, lymphoma, and other types of cancer. One study ...

Humira comes next with sales of $10.3 billion, followed by Gilead’s HIV drug Biktarvy ($10 bn), Pfizer’s breast cancer drug Ibrance ($9 billion), Johnson & Johnson’s Stelara for inflammatory ...

Looking forward, AbbVie's pipeline is weighted more toward new cancer and immunology drugs. The company should be able to leverage its solid entrenchment with Humira and Imbruvica to launch the ...

In a statement NHS England said the deal would pay for the equivalent of 11,700 more community nurses, or 19,800 breast cancer treatments. Humira went off patent last month, allowing a group of ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Humira treats the same conditions — and then ... negative hit due to a tax charge and milestone expenses. Revenue from cancer ...

With Skyrizi now capturing 1 in 3 in place UC patients, we highlight that the company’s I&I portfolio appears poised to continue growing through more significant Humira erosion,” analyst Evan ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...